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Introduction
Surface plasmon resonance (SPR) is a powerful technique for
the kinetic characterization of biomolecular interactions. This
technique requires the immobilization of one part of an inter-
acting pair to a sensor-chip surface, over which the second
part is passed in solution. Binding of the soluble analyte to the
immobilized ligand generates an SPR sensorgram, which is a
plot of arbitrary response or resonance units against time. The
resonance units result from the change in refractive index at
the chip surface upon analyte binding, as measured by sensi-
tive optical apparatus. The generated data can be used to cal-
culate the kinetic parameters of an interaction, such as associa-
tion and dissociation rate constants and hence affinity, as well
as the equilibrium constant of the interaction.[1–3] Common
methods for protein immobilization involve covalent coupling
on an SPR chip surface to naturally occurring amine or thiol
groups within the protein. Immobilization at amines occurs
after reaction with N-hydroxysuccinimide (NHS) esters coupled
to the chip surface during manufacture.[4] For thiol coupling,
reactive disulfide or maleimide groups can be introduced on
the chip surface. Other functional groups, such as aldehydes,
can also be chemically introduced in the protein to allow spe-
cific coupling to the chip surface;[5] affinity fusion tags, such as
glutathione S-transferase, maltose binding protein, poly-histi-
dine tags in combination with glutathione, amylose and nickel-
NTA-functionalized surfaces have also been used.[1, 3] SPR has
been used to study numerous interactions in biological sys-
tems, including those of penicillin-binding proteins (PBPs).
PBPs are peptidoglycan (PG) synthesis enzymes responsible
for the final steps in the production of the major component
of the bacterial cell wall.[6] PG is a mesh-like heteropolymer
composed of glycan strands interconnected by short peptides,
and is synthesized at the outer leaflet of the cytoplasmic mem-
brane. It is synthesized from lipid II by two enzymatic reac-
tions: polymerization of glycan strands by glycosyltransferase
(GTase) reactions, and cross-linkage of peptides by transpepti-
dase (TPase) reactions.[7–9] PBPs form a family of enzymes with
members capable of either TPase activity or both GTase and
TPase; they are so named because they readily form covalent
complexes with penicillin and other b-lactam antibiotics at
their TPase domains.[10–12] All PG synthases are anchored to the
cytoplasmic membrane by a single transmembrane helix, with
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the catalytic site on the outside. Escherichia coli is the best-
studied model organism for the interactions of PG enzymes.
PBP1B, a major E. coli PG synthase, has both GTase and TPase
activities.[13–15] Several interactions of PBP1B have been charac-
terized by SPR, including with other PG synthesis enzymes
(PBP3, MltA-MipA) and regulatory proteins (LpoB, CpoB,
FtsN).[16–20] SPR was also used to demonstrate dimerization of
PBP1B.[21] In all these examples, PBP1B (or PBP3) was immobi-
lized onto the chip surface at its TPase domain. This was ach-
ieved by coupling ampicillin to the chip surface and subse-
quently applying the PBP, thereby resulting in a covalent inter-
action of ampicillin with the active site of the TPase domain of
the PBP.
The oriented coupling of PBPs to the chip surface via ampi-
cillin is suboptimal in some cases. As the TPase active site is
occupied in this immobilization strategy, any interaction inter-
faces proximal to this position can be occluded and/or altered
compared to the apo state. Furthermore, in the cell PBPs are
anchored in the cytoplasmic membrane by an N-terminal
transmembrane helix, with the majority of the protein oriented
outwards and the TPase domain typically furthest from the
point of anchoring (Figure 1). Thus, immobilization of a PBP by
its TPase domain gives a contrary orientation to that in vivo,
thus exposing the GTase domain and membrane anchor and
potentially occluding interaction sites or hindering access of
analyte molecules.
To address this, we have designed a new immobilization
method, based on site-specific labeling, that can be generally
applied to any (membrane) protein. Many different bioorthog-
onal chemical reactions have been described to site-specifically
label proteins for surface immobilization.[22, 23] We chose to
anchor PBP1B to a chip surface by site-specific incorporation
of an azide-containing unnatural amino acid in the N-terminal
sequence of the protein (Figure 1), followed by covalent at-
tachment to immobilized dibenzylcyclooctyne by copper-free
click chemistry, as this reaction occurs spontaneously under
physiological conditions and does not need metal catalysts,
which can have undesirable effects on protein activity.[23] Im-
mobilization by this method yields the correct topological ori-
entation of the protein with an accessible and unaltered TPase
domain, thereby allowing characterization of interactions with
this domain.
Results and Discussion
Confirmation of the presence of the azide in the PBP1B
mutants by coupling to a cyclooctyne-containing
fluorescent dye
An azide-containing unnatural amino acid was incorporated in
the N-terminal tail of the protein by using nonsense suppres-
sion mutagenesis. This azide was used to covalently attach the
protein to the dibenzylcyclooctyne-coated chip surface by
copper-free click chemistry. Because this is a new method and
there is no information about the efficiency of this immobiliza-
tion method and the dependency on the position of the azide,
we substituted three adjacent amino acids in the N-terminal
region of PBP1B for the unnatural amino acid p-azidophenyl-
alanine. By site-directed mutagenesis, the codon for Gly53,
Lys54, or Gly55 of PBP1B was mutated to an amber (TAG)
codon. When each mutated PBP1B variant was expressed with
an orthogonal tRNA/aminoacyl-tRNA synthase pair that recog-
nizes TAG and is specific for the incorporation of the unnatural
amino acid p-azidophenylalanine, three mutant proteins were
produced: azidophenylalanine in place of either Gly53, Lys54,
or Gly55. In order to verify azide incorporation, we incubated
purified protein with a fluorescent dye containing a cyclooctyne
group, which spontaneously reacts with the azide (Figure 2 A).
In this way, the azide-containing proteins are fluorescently
tagged. This reaction mixture was separated by SDS-PAGE, and
the gel was scanned with a florescence scanner to visualize
labeled protein, then stained with Coomassie Brilliant Blue to
assess the total protein content loaded. The azide was indeed
incorporated into all three mutant proteins, according to the
fluorescence signals (Figure 2 B). An excess of cyclooctyne-con-
taining dye was needed for an efficient reaction under these
conditions (1:1 vs 10:1). Incubation with wild-type protein did
not result in fluorescence, thus showing that the reaction was
specific.
Azide-containing PBP1B proteins show both GTase and
TPase activity in an in vitro peptidoglycan synthesis assay
For the implementation of our SPR method, we used fully
active PBP1B proteins (both GTase and TPase activities). We
performed an in vitro PG synthesis assay to verify that the
Figure 1. Crystal structure of PBP1B (PDB ID: 3FWL)[34] showing the previous-
ly used immobilization site (serine residue in the active site of the TPase
domain) and the site used in our immobilization strategy (cytoplasmic tail).
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azide-containing proteins retained both activities. Protein was
incubated in a buffer containing all the ingredients needed for
activity, supplemented with fluorescently labeled lipid II for the
detection of the produced polymers. This labeled lipid II
cannot be used as a substrate for the crosslink-forming TPase
reaction, as the position of the attached fluorophore is the
position used in crosslink formation. Furthermore, E. coli PBP1B
needs a lipid II version with a meso-diaminopimalic acid at this
position of the donor peptide for crosslink formation, and the
labeled version originated from a lysine version. Therefore, un-
labeled meso-diaminopimalic acid lipid II was included in the
mixtures for the TPase reaction.
In order to analyze solely GTase activity, penicillin G was
added to some of the reaction mixtures (to inhibit TPase activi-
ty). As a result of GTase activity, sugar moieties of lipid II were
polymerized into glycan strands. These glycan strands were
separated by Tris/Tricine SDS-PAGE.[24–29] The glycan polymers
separated by size, with smaller ones visible as separated bands
in the lower region of the gel, and longer strands as a smear
in the higher region (Figure 3, right). Unincorporated lipid II
monomers are visible at the bottom of the gel (Figure 3,
bottom left). Crosslinked PG is visible as a band at the bottom
of the well in the absence of penicillin G (Figure 3, top left), be-
cause the crosslinked PG network is too large to enter the gel.
Figure 2. Left : The three PBP1B variants have an incorporated azide that specifically reacts with a cyclooctyne-containing fluorescent dye. Right: The variants
were expressed in E. coli, purified by nickel affinity chromatography, and incubated overnight at RT with the cyclooctyne-containing fluorescent dye Mega-
stokes 608. Samples were separated by SDS-PAGE. The gel was scanned with a florescence scanner (upper image) to visualize the labeled proteins and then
stained with Coomassie blue (lower) to visualize total protein content. WT protein was not labeled. The ratios of dye to protein are indicated (above).
Figure 3. In vitro PG synthesis assay shows that all three azido-protein variants perform both GTase and TPase reactions. Purified PBP1B was incubated at
30 8C with a mixture of labeled and unlabeled lipid II, and samples were taken at the indicated time-points. Produced glycan chains were separated by size
on a Tris/Tricin SDS-PAGE gel. The overall increase in chain length and decrease in intensity of the free lipid II band over time indicates GT activity of the three
mutant proteins. TPase activity is detected by the high intensity bands at the top of the gel for reactions with penicillin G, which inhibits the TPase reaction.
Cross-linked PG does not enter the gel.
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These results show that the three mutant proteins are fully
active (both GTase and TPase) in this in vitro PG synthesis
assay.
Use of azide-incorporated PBP1B for site-specific
immobilization on an SPR chip
Optimization of immobilization conditions : For immobilization
of the azide-containing PBP1B variants, we used an amine-
functionalized chip surface to perform the SPR experiments.
First, it was functionalized by using the amine-reactive sulfo-di-
benzylcyclooctyne-NHS ester. As the efficiencies of functionali-
zation and the subsequent click-reaction with the azide in the
proteins were not known, we varied the concentration of
sulfo-dibenzylcyclooctyne-NHS ester from 0.25 to 1 mm and
the protein concentration from 0.04 to 0.5 mm. In order to
identify the optimal conditions for PBP1B immobilization and
interaction measurement, we used the well-characterized inter-
action between PBP1B and LpoB as a test system, as the kinet-
ic parameters of this interaction have been well estab-
lished.[18, 24, 30]
The amount of protein bound to a chip surface is represent-
ed by the response of local ligand (RLL) value, expressed in res-
onance units (RUs). 1 RU corresponds to approximately
1 pg mm@2, and the binding capacity (Rmax) depends on the
amount of protein immobilized on the chip surface according
to Rmax = (analyte MW/ligand MW) V RL V Sm (stoichiometric
ratio). A typical RLL values for our type of measurement is
1000 RU.
All three azido-protein variants were well immobilized on
the chip surface, thus suggesting that the position of the azide
is not crucial for immobilization efficiency in this case
(Figure 4). The highest protein concentration tested (0.5 mm)
resulted in the highest amount of immobilized protein on the
chip without causing protein aggregation, which would render
the protein inactive. Sulfo-dibenzylcyclooctyne-NHS ester con-
centration did not affect immobilization efficiency or the SPR
signals (data not shown). Therefore, we used 0.5 mm protein
and 1 mm sulfo-dibenzylcyclooctyne-NHS ester with variant
Gly55 in further experiments. This variant was slightly more
active in the in vitro PG synthesis assay than PBP1B-Gly53, and
on average produced SPR curves with a higher signal than
PBP1B-Lys54 upon injection of LpoB (PBP1B-binding analyte).
We decided to include an azidoethanol blocking step because
this resulted in slightly higher responses under the above con-
ditions and, more importantly, in order to block possible hy-
drophobic interactions between injected protein and free cy-
clooctyne groups on the chip. A blocking step (with ethanola-
mine) is included in the ampicillin immobilization method, so
including a blocking step in our method also allowed a better
comparison between the two methods. The results of the all
optimization experiment are shown in Table S2 in the Support-
ing Information.
Do the immobilized PBP1B variants still interact with LpoB
in a similar way?
Next, we immobilized PBP1B on every spot of the chip (except
for some control spots) with the optimized conditions. Injec-
tion of LpoB over the PBP1B-immobilized SPR surface resulted
as an increase in RU; stopping injection resulted in release of
the interacting molecules, and thus a decrease in RU.
The sensorgram for the injection of LpoB over immobilized
PBP1B (Figure 5, left) shows that LpoB has a very quick associa-
tion with PBP1B, as published before.[18] The immediate rise in
RU to the equilibrium made it impossible to determine the as-
sociation rate constant. The same holds for the dissociation of
LpoB from PBP1B when injection ceased. The maximum reso-
Figure 4. Top: Immobilization of the three azido-protein variants on the SPR
surface. The amount of immobilized protein is represented by the RLL value:
all thee variants were immobilized on the SPR chip surface at different pro-
tein concentrations. Middle and bottom: Example SPR response curves for
two PBP1B Gly55AzF immobilized spots upon LpoB injection.
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nance unit (maxRU) values for the different analyte concentra-
tions were plotted by non-linear regression with the formula
y = Bmaxx/(KD + x) (one site saturation in the simple ligand-bind-
ing tool of SigmaPlot), in order to determine the equilibrium
constant. This resulted in calculated KD values of 0.71–0.97 mm
with a standard deviation of :0.052, which is close to the
0.81:0.08 mm found by Egan et al.[18] The small differences in
equilibrium constant could have arisen from slight differences
in buffer composition, pH or temperature at which the meas-
urements were performed.
These results show that this new PBP1B-immobilization tech-
nique, with an azide incorporated in the protein cytoplasmic
tail, is a good alternative to the ampicillin-immobilization
method for SPR experiments. We show that it produces similar
results when analyzing the interaction of PBP1B with LpoB. We
have not yet identified the specific interactions (of the TPase
domain of PBP1B) that would be preferably analyzed by our
new immobilization strategy. Incubation of PBP1B with ampicil-
lin prior to immobilization did not alter the binding of LpoB to
PBP1B (data not shown), thus suggesting that the interaction
is independent on the state of the TPase domain. This also
implies that the activation of the TPase by LpoB does not
depend on the availability of a TPase substrate, consistent with
primary activation of the GTase by LpoB.[18, 31]
This new immobilization method can be used for the immo-
bilization of any desired protein, and creates the possibility to
control the orientation of the protein by the site specific incor-
poration of the azide. Replacing different surface amino acids
and homogeneously orientating the protein on the chip sur-
face opens the possibility to study the topology-dependence
of interactions of membrane proteins.
Experimental Section
Bacterial strains and plasmids: Escherichia coli DH5a cells were
used for DNA amplification. E. coli BL21(DE3) cells were used for
protein expression. Plasmid pDML924 carrying the mrcB gene,
which encodes the N-terminal His6-tagged variant PBP1Bg (a gift
from Mohammed Terrak, University of Liege, Belgium),[15] was used
for overexpression of PBP1B and as a template for the generation
of PBP1B mutants. Plasmid pEvol-pAzF encoding the orthogonal
aminoacyl tRNA synthase-tRNACUA pair was used for incorporation
of p-azidophenylalanine at the site of an amber mutation. Plasmid
pET28LpoB (signal sequence and lipid anchor of LpoB replaced by
an oligohistidine tag, LpoB(sol)) was used for the overexpression of
LpoB (sol).[18]
Site-directed mutagenesis: The amber mutants were created by
mutagenesis PCR (primers in Table S1). The reaction mixture con-
tained fwd and rev primer (125 ng), dNTPs (10 mm each, 1 mL),
template DNA (DNA at an end concentration of 1.23 ng mL@1, 1 mL
of a 61.5 ng mL@1) and Phusion DNA polymerase (1 U, 0.5 mL;
Thermo Fisher Scientific) in a total volume of 50 mL in [1 V Phusion
buffer] . We performed 17 cycles of 30 s at 98 8C, 1 min at Tm (de-
pending on the primers), and 5 min at 72 8C. PCR products were di-
gested with DpnI (10 U; Fermentas) and amplified in E. coli DH5a.
Sequencing confirmed the intended mutations.
Expression and purification of azide-containing PBP1B and
LpoB: E. coli BL21 (DE3) cells were co-transformed with pDML924
containing the amber mutation and pEvol-pAzF, and grown at
37 8C to OD600 = 0.5–0.6. tRNA/tRNA synthase production was in-
duced with arabinose (0.04 %), and freshly prepared p-azidophenyl-
alanine, (0.1 mm in 1 m NaOH) was added. After 30 min, protein
production was induced with IPTG (1 mm). After 2 h, cells (1 L cul-
ture) were harvested by centrifugation, and resuspended in buf-
fer A (18 mL; Tris·HCl (20 mm pH 8.0), NaCl (300 mm), imidazole
(5 mm)) supplemented with PMSF (0.1 mm) and 1 cOmplete EDTA-
free protease inhibitor tablet (Roche). Cells were lysed by sonifica-
tion in Sonifier 250 (Branson Ultrasonics, Danbury, CT) with a micro-
tip. Intact cells were removed by centrifugation (3500 g, 10 min),
then the lysate was centrifuged (200 000 g, 90 min, 4 8C) in a WX80
Ultra with a T865 rotor (Sorvall). The membrane fraction (pellet)
was solubilized in buffer A (12 mL) supplemented with Triton X-
100 (2 %), by stirring for 2 h at 4 8C. Insoluble material was re-
moved by centrifugation (200 000 g, 90 min, 4 8C). Solubilized pro-
teins were incubated with Ni-Sepharose beads (300 mL; GE Health-
care) overnight at 4 8C. The beads were centrifuged (3500 g, 3 min,
4 8C), and the unbound fraction was discarded. The beads were
washed with buffer A (5 V 10 mL) containing imidazole (50 mm)
and Triton X-100 (0.1 %), then with buffer A (3 V 2 mL) containing
imidazole (100 mm) and Triton X-100 (0.1 %). Proteins were eluted
in buffer A (4 V 2 mL) containing imidazole (500 mm) and Triton X-
100 (0.1 %). Fractions were dialyzed by using a 500 Da membrane
against dialysis buffer A (Tris·HCl (20 mm pH 8.0), NaCl (300 mm),
MgCl2 (10 mm), Triton X-100 (0.1 %), glycerol (10 %)) at 4 8C for
48 h. Protein content for all three mutants was analyzed with a
Figure 5. Left : SPR sensorgram for injection of LpoB at different concentrations over a PBP1B immobilized on a chip. Right: Analysis of the SPR data by non-
linear regression for one-site saturation in the simple ligand-binding tool of SigmaPlot. The plot of maximum RU against analyte concentration determines
the equilibrium constant : KD = 0.84:0.05 mm, which is close to the 0.81:0,08 mm previously found.[18]
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BSA range on a Coomassie-stained gel (:0.2 mg mL@1, = :2.25 mm).
Protein was stored at @20 8C.
E. coli BL21 (DE3) cells harboring plasmid pET28LpoB were grown
at 30 8C to OD578 = 0.5–0.6. Overexpression was induced by the ad-
dition of IPTG (1 mm), and cells were incubated for a further 3 h at
308C. Cells were harvested by centrifugation and resuspended in
buffer B (Tris·HCl (25 mm, pH 7.5), MgCl2 (10 mm), NaCl (500 mm),
imidazole (20 mm), glycerol (10 %)), supplemented with DNase
(Sigma bovine pancreatic DNase, 1 spatula point), protease inhibi-
tor cocktail (Sigma 1/1000 dilution), and PMSF (0.1 mm). Cells were
disrupted by sonication. The lysate was centrifuged (130 000 g, 1 h,
4 C), and the supernatant was applied to a 5 mL HisTrap HP
column (GE Healthcare) attached to an gKTA Prime + system (GE
Healthcare;1 mL min@1). The column was washed with four volumes
of buffer B, followed by elution of bound proteins with buffer C
(Tris·HCl (25 mm, pH 7.5), MgCl2 (10 mm), NaCl (500 mm), imidazole
(400 mm), glycerol (10 %)). In order to remove the His tag from His-
LpoB(sol), restriction grade thrombin (50 U mL@1; Merck Millipore)
was added. The protein was dialyzed against dialysis buffer B
(Tris·HCl (25 mm, pH 8.3), NaCl (100 mm), glycerol (10 %)) for 18 h
at 4 8C. LpoB(sol) was applied to a 5 mL HiTrap Q HP column (GE
healthcare) attached to an gKTA Prime + (GE Healthcare) at
0.5 mL min@1 and collected in the flow-through. LpoB(sol) was con-
centrated to 4–5 mL in a VivaSpin column (MW cut-off 6000 Da)
and applied to a Superdex 200 HiLoad 16/600 column at
1 mL min@1 for size-exclusion chromatography in buffer D (HEPES/
NaOH (25 mm, pH 7.5), NaCl (1 m), glycerol (10 %)). Finally, the pro-
tein was dialyzed against storage buffer (HEPES/NaOH (25 mm,
pH 7.5), NaCl (500 mm), glycerol (10 %)) and stored at @80 8C.[18]
Confirmation of the presence of the azide in PBP1B mutants by
coupling of cyclooctyne-containing fluorescent dye and SDS-
PAGE analysis: Protein solution (10 mL, 2.25 mm) was incubated
with MegaStokes dye 608 (2.25 or 22.5 mm; Sigma–Aldrich) over-
night at RT. Laemmli sample buffer (without DTT) was added, and
samples were run on an 8 % SDS-PAGE gel. Fluorescence was ana-
lyzed with a Typhoon 9400 scanner (GE healthcare), and protein
content were estimated by Coomassie Blue staining.
Protein activity test using an in vitro PG synthesis assay and vis-
ualization on Tris/Tricin SDS-PAGE: PBP1B (1 mm) was incubated
with ATTO550 lipid II (10 mm ; synthesized as previously de-
scribed[32, 33]) and m-DAP lipid II (100 mm), in HEPES (20 mm, pH7.5)
with NaCl (150 mm), MgCl2 (10 mm), and Triton X-100 (0.05 %) at
30 8C. Penicillin G (1 mg) was added to some reactions to be able to
analyze only the GT reaction. Samples (15 mL) were taken at various
time-points, and the protein was inactivated by boiling (99 8C,
5 min). The samples were dried in a SpeedVac, dissolved in sample
buffer (4 mL; Tris·HCl (60 mm, pH 8.8), glycerol (25 %), SDS (2 %)),
and analyzed by Tris/Tricine SDS-PAGE. Gels were prepared at
a final concentration of 9 % T, 2.6 % C (T: total percentage of both
acrylamide and bisacylamide; C: percentage of bisacrylamide rela-
tive to T). This was prepared in gel buffer (Tris (0.5 m, pH 8.45), SDS
(0.13 %)). Gels were run with anode buffer (Tris (0.1 m, pH 8.8)) and
cathode buffer (Tris (0.1 m, pH 8.25), tricine (0.1 m), SDS (0.1 %)) at
30 mA (maximum voltage 200 V). Gels were scanned in the Ty-
phoon 9400.
SPR studies: An IBIS-MX96 (IBIS Technologies, Enschede, The Neth-
erlands) was used. PBP1B variants were immobilized on the surface
of a SensEye P-NH2 sensor (IBIS) coated with sulfo-dibenzylcyclooc-
tyne-NHS ester (Jena Bioscience, Jena, Germany). After activation
of the chip, the spots were coated for 60 min with sulfo-dibenzyl-
cyclooctyne-NHS ester (1, 0.5, or 0.25 mm in HEPES (20 mm,
pH 7.5)). After a rinse with PBS, PBP1B (0.5, 0.2, or 0.04 mm) in run-
ning buffer (Tris/maleate (10 mm, pH 7.5), NaCl (150 mm), Triton X
100 (0.05 %)) was spotted for 30 min. After a rinse with running
buffer, excess sulfo-dibenzylcyclooctyne-NHS ester was blocked
with azidoethanol (0.5 m in running buffer) for 10 min. The amount
of immobilized protein ranged from 1000 to 3000 RU (1 RU corre-
sponds to approximately 1 pg of protein per mm2). Some spots
were controls with different treatments (Table S2). Analytes in run-
ning buffer were injected at different concentrations: 2 min base-
line, 10 min association, 5 min dissociation, and two times 30 s of
regeneration with running buffer (containing NaCl (1 m)) were re-
corded. The sensorgrams were evaluated with SPRintX (IBIS), and
the parameters of the interaction were calculated in SigmaPlot
(Systat Software, San Jose, CA) by using the simple ligand-binding
tool and one-site saturation.
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